Friday, April 4, 2025
4/4/2025
ADAP Shortfall Relief - In January 2010, the NC ADAP instituted a waiting list for all new applicants and reduced the Program’s formulary to only cover antiretroviral medications and a small list of medications used to treat opportunistic infections. In July 2010, the waiting list was reduced, and program enrollment was restored. However, the program reduced the financial eligibility criteria from 300% FPL to 125% FPL, started a waiting list for applicants with income between 126% and 300% FPL, and kept the reduced formulary in place. The program has received ERF funding since 2010. In 2010 ($2,242,421), 2011 ($3,000,000) and 2012 ($3,000,000), the ERF funds were used to reduce the number of individuals on the waiting list and prevent further cost containment measures. In 2012, the waiting list was eliminated, and the financial eligibility was restored to 300% FPL. In 2013, the formulary was restored to include a robust list of medications related to HIV, treatment of side effects, and other comorbidities. The 2013 ($3,000,000), 2014 ($3,000,000), 2015 ($2,691,965), 2016 ($2,672,688), 2017 ($3,000,000), 2018 ($3,000,000), 2019 ($3,000,000), 2020 ($1,923,696), 2021 ($5,524,365), 2022 ($5,811,053), 2023 ($6,407,650), and 2024 ($6,584,874) ERF funds have been used to support clients moved off the waiting list between 2010 and 2012 and to prevent a future waiting list and/or additional cost containment measures, such as a reduced formulary or a reduced financial eligibility. The NC ADAP is requesting a total of $7,000,000 in emergency relief funding. The amount requested is an increase compared to last year’s ERF funding award. Increased ERF funding would contribute to funding stability in an otherwise instable environment, especially amid COVID-19 and a projected increase of HMAP clients. The Program will utilize all 2025 ADAP ERF funds awarded to support clients removed from the Program’s waiting list with the first three ADAP ERF awards (2010 – 2012) and to prevent a future waiting list and/or other cost containment measures during the projected grant period of 4/1/25 to 3/31/26. This will be accomplished by adding ERF funds to the available budget for medication purchasing for clients served through the direct purchase pharmacy program for uninsured clients. The receipt of $7,000,000 in ERF funding will allow the Program to support a total of 649 individuals (for one year) through medication purchasing. None of the requested funds will be used for staffing or evaluation. Current program projections and financial forecasts indicate an increased need for emergency relief funds. There is no expectation that this special funding will be renewed after this year of support, and our projections indicate that there are no other funds available which could be used to cover these costs once this support ends.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).